Related Experiment Video
Updated: Jul 19, 2025

Yeast As a Chassis for Developing Functional Assays to Study Human P53
Published on: August 4, 2019
AI-powered discovery of a novel p53-Y220C reactivator
Shan Zhou1, Dafei Chai1, Xu Wang1
1Department of Medicine, Section of Epidemiology and Population Sciences, Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, United States.
Introduction:
The p53-Y220C mutation is one of the most common mutations that play a major role in cancer progression.
Methods:
In this study, we applied artificial intelligence (AI)-powered virtual screening to identify small-molecule compounds that specifically restore the wild-type p53 conformation from p53-Y220C. From 10 million compounds, the AI algorithm selected a chemically diverse set of 83 high-scoring hits, which were subjected to several experimental assays using cell lines with different p53 mutations.
Results:
We identified one compound, H3, that preferentially killed cells with the p53-Y220C mutation compared to cells with other p53 mutations. H3 increased the amount of folded mutant protein with wild-type p53 conformation, restored its transcriptional functions, and caused cell cycle arrest and apoptosis. Furthermore, H3 reduced tumorigenesis in a mouse xenograft model with p53-Y220C-positive cells.
Conclusion:
AI enabled the discovery of the H3 compound that selectively reactivates the p53-Y220C mutant and inhibits tumor development in mice.
Insights
Artificial intelligence identified compound H3, which restores wild-type p53 conformation in the p53-Y220C mutation. This compound selectively kills cancer cells and inhibits tumor growth in mice.
Area of Science:
- Oncology
- Molecular Biology
- Drug Discovery
Background:
- The p53-Y220C mutation is a frequent driver of cancer progression.
- Restoring wild-type p53 function is a therapeutic strategy for cancers with this mutation.
Purpose of the Study:
- To identify small-molecule compounds that restore wild-type p53 conformation in the p53-Y220C mutant.
- To evaluate the efficacy of identified compounds in preclinical cancer models.
Main Methods:
- Artificial intelligence (AI)-powered virtual screening of 10 million compounds.
- Experimental validation using cell lines with various p53 mutations.
- In vivo efficacy assessment in a mouse xenograft model.
Main Results:
- AI identified 83 high-scoring compounds, with H3 showing preferential activity against p53-Y220C mutant cells.
- Compound H3 restored wild-type p53 conformation and transcriptional activity.
- H3 induced cell cycle arrest, apoptosis, and reduced tumor growth in mice.
Conclusions:
- AI facilitated the discovery of H3, a selective p53-Y220C reactivator.
- H3 demonstrates therapeutic potential for inhibiting tumor development in p53-Y220C-driven cancers.
More Related Videos
Related Concept Videos
Abnormal Proliferation
Covalently Linked Protein Regulators
These groups modify specific amino acids in a protein....
Conservative Site-specific Recombination and Phase Variation
The recognition sites for Cre recombinase called LoxP...

